View original publication
- There is good evidence based on effectiveness data to recommend in favour of routine vaccination of children aged 12-15 months and catch-up vaccination of children to 12 years for the prevention of VZV illness.
(Grade A recommendation)
- There is fair evidence for the vaccination of susceptible adolescents and adults.
(Grade B recommendation)
Further clinical trials would be needed to provide better data on cost-effectiveness, mortality and hospitalization; long-term effectiveness in adults and to compare effectiveness of one- versus two-dose regimens in adolescents and adults.